<DOC>
	<DOCNO>NCT02030964</DOCNO>
	<brief_summary>This study combine oral drug call DFMO celecoxib ( also oral ) two IV chemotherapy medicine call cyclophosphamide topotecan . - To find high dose DFMO give celecoxib , cyclophosphamide topotecan without cause severe side effect . - To find side effect see give DFMO different dose level celecoxib , cyclophosphamide topotecan . - To measure level DFMO blood different dose level . - To determine tumor get small treatment DFMO , celecoxib , cyclophosphamide topotecan . - To determine specific gene change tumor make prone side effect affect tumor 's response combination DFMO , celecoxib , cyclophosphamide topotecan . - To determine amount normal chemical body call polyamines go response DFMO , celecoxib , cyclophosphamide topotecan , whether likely good response treatment .</brief_summary>
	<brief_title>N2012-01 : Phase 1 Study Difluoromethylornithine ( DFMO ) Celecoxib With Cyclophosphamide/Topotecan</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Patients must &gt; 2 year &lt; 30 year age register study . Patients must recurrent/progressive highrisk neuroblastoma , refractory highrisk neuroblastoma less partial response standard treatment persistent highrisk neuroblastoma least partial response standard treatment . All patient must least ONE site evaluable disease . Patients must adequate heart , kidney , liver bone marrow function . Patients bone marrow disease must still adequate bone marrow function enter study . Patients ongoing serious medical issue must approve study chair prior registration . Females childbearing potential negative pregnancy test . Patients pregnant , breast feeding , unwilling use effective contraception study Patients status post allogeneic stem cell transplant . Patients , opinion investigator , may able comply safety monitoring requirement study . Patients disease major organ system would compromise ability withstand therapy . Patients hemodialysis . Patients active uncontrolled infection . Patients prolonged antifungal therapy still eligible culture biopsy negative suspect radiographic lesion meet organ function criterion . Patients active bleed GI tract patient symptom associate stomach irritation ( know gastritis ) . Patients seizure within 12 month prior enrollment patient receive anticonvulsant therapy seizure disorder . Patients know AspirinHypersensitivity triad ( asthma , allergic rhinitis , ASA hypersensitivity ) . Patients know hypersensitivity celecoxib NSAIDs , aspirin sulfonamide .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>